 |
ZUG, Switzerland, Jan. 20, 2022 /PRNewswire/ — Medison, a global pharma company focused on providing access to highly innovative therapies to patients in international markets (“Medison”), is proud to announce the joining of Victor Papamoniodis in the newly created position of VP International Markets. Victor will be based in Zug, Switzerland, Medison’s international headquarters.
Victor Papamoniodis, VP International Markets, Medison Pharma
Victor will head Medison’s markets outside of Israel and will focus on scaling up the company’s presence across markets, while growing and nurturing relationships with Medison’s global partners.
Prior to joining Medison, Victor held the position of VP International & Emerging Markets at Apellis Pharmaceuticals, Inc. Prior to that, he spent 9 years at Vertex Pharmaceuticals Incorporated as GM for Distributors & Expansion Markets, responsible for multiple regions, including CEE, LATAM, Russia & MENA.
“I am delighted to join Medison’s global leadership at an exciting time of rapid growth and expansion into new markets. Medison creates a real paradigm shift in the pharma industry, positioning itself as the next-gen partner for biotech companies who wish to access international markets and serve patients in need,” said Victor Papamoniodis.
“Medison is set out to change patients’ lives in international markets, bridging the unbearable access gap and making the most innovative therapies accessible to patients,” said Meir Jakobsohn, Founder and CEO of Medison. “The experience and capabilities that Victor brings will take our international platform to the next level.”
“Adding Victor’s capabilities will accelerate Medison’s expansion into additional markets and regions, building a true unified platform for the benefit of partners and patients, globally,” added Gil Gurfinkel, VP Corporate Development of Medison.
About Medison Pharma
Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets. Medison is the first to create an international commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of multi-territorial partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach. To learn more visit www.medisonpharma.com.
Medison Contact
Maya Nix
Corporate Communications Lead
mayan@medison.co.il
+972-3-925-0260
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
